Mammoth Biosciences
Maneesh Jain is a prominent leader in the biotechnology and healthcare sectors, currently serving as CEO and Co-founder of Mirvie, a company focused on addressing pregnancy complications through innovative liquid biopsy technologies. Jain also holds board positions at Mammoth Biosciences, Adela, and Mission Bio, contributing to advancements in CRISPR applications, early cancer detection, and single-cell analysis platforms. As CEO and President of Cirina Inc., Jain was instrumental in developing the first non-invasive blood test for early cancer detection. Jain's leadership roles extend to Butterfly Network, where a portable ultrasound device was commercialized, and as an angel investor with Life Science Angels. An academic background includes a PhD in Applied Physics from Stanford University and a BSc in Physics/EE from Caltech.
This person is not in the org chart
Mammoth Biosciences
3 followers
Mammoth Biosciences is harnessing the diversity of nature to power the next-generation of CRISPR products. Through the discovery and development of novel CRISPR systems, the company is enabling the full potential of its platform to improve lives by reading and writing the code of life. Mammoth aims to democratize disease detection with an easy and affordable point-of-care test that allows real-time and simultaneous detection of multiple conditions. By leveraging its internal research and development and exclusive licensing to Cas12, Cas13, Cas14, and CasΦ, Mammoth can provide enhanced diagnostics and genome editing for life science research, healthcare, agriculture, biodefense and more. Based in San Francisco, Mammoth Biosciences is co-founded by CRISPR pioneer Jennifer Doudna and principal founders Trevor Martin, Janice Chen, and Lucas Harrington. The firm is backed by top institutional investors including Mayfield, NFX, and 8VC, Decheng and leading individual investors including Brook Byers, Tim Cook, and Jeff Huber.